Certolizumab pegol in Crohn's disease.
Certolizumab pegol is a humanized Fab' fragment monoclonal antibody to tumor necrosis factor alpha (TNF-alpha). PEGylation increases its half-life, and it is administered subcutaneously to treat immune-mediated inflammatory diseases such as Crohn's disease and rheumatoid arthritis. Certolizumab pegol improves quality of life and reduces clinical disease activity. Inflammatory markers such as C-reactive protein (CRP) also decrease after administration of certolizumab pegol. The dose for induction of remission is 400 mg subcutaneously at weeks 0, 2 and 4. The dose for maintenance of remission is 400 mg sc given every four weeks. The safety profile is comparable with other anti-TNF agents, and the major adverse events are related to infections. This article reviews the published data regarding the efficacy and safety of certolizumab pegol.
Patel
V K
VK
Gastrointestinal Section, Imperial College London, Hammersmith Hospital, London, U.K.
Ghosh
S
S
D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008956:Models, Chemical; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol